NCT01709292 2026-04-16
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT04462471 2025-09-08
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02145143 2025-06-18
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT02456701 2017-09-05
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Celldex Therapeutics
Phase 1 Completed